Drug Profile

CNTY 104

Alternative Names: CNTY-104

Latest Information Update: 16 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Century Therapeutics
Class Antineoplastics; CAR-NK cell therapies; CAR-T cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

12 Mar 2025 Bristol Myers Squibb terminates its collaboration and licensing agreement with Century Therapeutics due to internal portfolio prioritisation
12 Mar 2025 Discontinued for Acute myeloid leukaemia in USA (Parenteral)
10 Jan 2022 Century Therapeutics and Bristol Myers Squibb enters into a collaboration agreement to develop CNTY 104

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com